Albany Molecular Res (AMRI) 16.20 $AMRI Global
Post# of 273254
Posted On: 09/25/2016 5:10:37 PM
Albany Molecular Res (AMRI) 16.20 $AMRI
Global Drug Discovery Market Report 2016-2022 - Analysis, Technologies & Forecasts - Key Vendors: Infosys, Charles River Labs, Albany Molecular Research - Research and Markets
BusinessWire - Tue Sep 20, 6:49AM CDT
Research and Markets has announced the addition of the "Global Drug Discovery Market Analysis 2016 - Forecast to 2022" report to their offering.
AMRI: 16.20 (+0.03)
Lifshitz & Miller Law Firm Announces Investigation of Accuride Corporation, Albany Molecular Research Inc., Emergent BioSolutions, Inc., Flowers Foods, Inc., Orbital ATK, Inc., Quorum Health Corp., Stericycle, Inc., and SunPower Corporation
PR Newswire - Wed Sep 07, 3:06PM CDT
Accuride Corporation (ACW)
EBS: 28.36 (-0.38), ACW: 2.57 (+0.01), SRCL: 79.54 (+0.28), SPWR: 8.52 (+0.27), QHC: 6.28 (+0.03), OA: 74.44 (-0.33), AMRI: 16.20 (+0.03), FLO: 15.54 (-0.13)
AMRI CEO to Present at Morgan Stanley Global Healthcare Conference
PR Newswire - Tue Aug 30, 7:00AM CDT
Albany Molecular Research Inc. (NASDAQ: AMRI) announced today that William S. Marth, AMRI's President and Chief Executive Officer, will present at the Morgan Stanley Global Healthcare Conference on Tuesday, September 13, 2016 at 3:30 p.m. ET. A live audio webcast of the presentation can be accessed at AMRI's Investor Relations web site at http://ir.amriglobal.com/events.cfm?CalendarID=2.
AMRI: 16.20 (+0.03), MS: 31.91 (-0.33)
AMRI CEO to Present at Baird 2016 Global Healthcare Conference
PR Newswire - Wed Aug 24, 7:00AM CDT
Albany Molecular Research Inc. (NASDAQ: AMRI) announced today that William S. Marth, AMRI's President and Chief Executive Officer, will present at the Baird 2016 Global Healthcare Conference on Wednesday, September 7, 2016 at 1:25 p.m. ET. A live audio webcast of the presentation can be accessed at AMRI's Investor Relations web site at http://ir.amriglobal.com/events.cfm?CalendarID=2.
AMRI: 16.20 (+0.03)
AMRI Licenses CRISPR-Cas9 Gene Editing Technology
PR Newswire - Tue Aug 23, 3:05PM CDT
AMRI (NASDAQ: AMRI) today announced that it entered into a non-exclusive commercial license agreement with the Broad Institute of MIT and Harvard for the use of CRISPR-Cas9 gene editing technology and has completed several projects for its customers. The company will continue to use the technology to enhance its drug discovery service offerings and internal research and development. Financial terms were not disclosed.
AMRI: 16.20 (+0.03)
Update in Lawsuit for Investors in Albany Molecular Research, Inc. shares announced by Shareholders Foundation
GlobeNewswire - Tue Aug 23, 9:05AM CDT
The Shareholders Foundation, Inc. announces that a lawsuit is pending in New York on behalf of certain purchasers of shares of Albany Molecular Research, Inc. (NASDAQ:AMRI) over alleged Securities Laws Violations by Albany Molecular Research.
AMRI: 16.20 (+0.03)
Ryan & Maniskas, LLP Announces Investigation of Albany Molecular Research Inc.
PR Newswire - Wed Aug 10, 5:00PM CDT
Ryan & Maniskas, LLP is investigating potential claims against the board of directors of Albany Molecular Research, Inc. ("Albany Molecular" or the "Company"
(NASDAQ: AMRI).
AMRI: 16.20 (+0.03)
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Albany Molecular Research, Inc. (AMRI)
PR Newswire - Tue Aug 09, 9:15AM CDT
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Albany Molecular Research, Inc. ("Amri" or the "Company" (NASDAQ: AMRI). Such investors are advised to contact Peretz Bronstein or his investor relations analyst, Yael Hurwitz at info@bgandg.com or 212-697-6484.
AMRI: 16.20 (+0.03)
Robbins Arroyo LLP Is Investigating the Officers and Directors of Albany Molecular Research, Inc. (AMRI) on Behalf of Shareholders
BusinessWire - Mon Aug 08, 12:03PM CDT
Shareholder rights law firm Robbins Arroyo LLP is investigating whether certain officers and directors of Albany Molecular Research, Inc. (NASDAQGS: AMRI) breached their fiduciary duties to the company and its shareholders by failing to implement adequate internal controls over the company's management and disclosure procedures. Albany Molecular Research, a contract research and manufacturing company, provides integrated drug discovery, development, and manufacturing services primarily in the United States, Europe, and Asia.
AMRI: 16.20 (+0.03)
AMRI Announces Second Quarter 2016 Results
PR Newswire - Thu Aug 04, 6:30AM CDT
AMRI (NASDAQ: AMRI) today reported financial and operating results for the second quarter ended June 30, 2016 and provided an update to its outlook for 2016.
AMRI: 16.20 (+0.03)
Global Drug Discovery Market Report 2016-2022 - Analysis, Technologies & Forecasts - Key Vendors: Infosys, Charles River Labs, Albany Molecular Research - Research and Markets
BusinessWire - Tue Sep 20, 6:49AM CDT
Research and Markets has announced the addition of the "Global Drug Discovery Market Analysis 2016 - Forecast to 2022" report to their offering.
AMRI: 16.20 (+0.03)
Lifshitz & Miller Law Firm Announces Investigation of Accuride Corporation, Albany Molecular Research Inc., Emergent BioSolutions, Inc., Flowers Foods, Inc., Orbital ATK, Inc., Quorum Health Corp., Stericycle, Inc., and SunPower Corporation
PR Newswire - Wed Sep 07, 3:06PM CDT
Accuride Corporation (ACW)
EBS: 28.36 (-0.38), ACW: 2.57 (+0.01), SRCL: 79.54 (+0.28), SPWR: 8.52 (+0.27), QHC: 6.28 (+0.03), OA: 74.44 (-0.33), AMRI: 16.20 (+0.03), FLO: 15.54 (-0.13)
AMRI CEO to Present at Morgan Stanley Global Healthcare Conference
PR Newswire - Tue Aug 30, 7:00AM CDT
Albany Molecular Research Inc. (NASDAQ: AMRI) announced today that William S. Marth, AMRI's President and Chief Executive Officer, will present at the Morgan Stanley Global Healthcare Conference on Tuesday, September 13, 2016 at 3:30 p.m. ET. A live audio webcast of the presentation can be accessed at AMRI's Investor Relations web site at http://ir.amriglobal.com/events.cfm?CalendarID=2.
AMRI: 16.20 (+0.03), MS: 31.91 (-0.33)
AMRI CEO to Present at Baird 2016 Global Healthcare Conference
PR Newswire - Wed Aug 24, 7:00AM CDT
Albany Molecular Research Inc. (NASDAQ: AMRI) announced today that William S. Marth, AMRI's President and Chief Executive Officer, will present at the Baird 2016 Global Healthcare Conference on Wednesday, September 7, 2016 at 1:25 p.m. ET. A live audio webcast of the presentation can be accessed at AMRI's Investor Relations web site at http://ir.amriglobal.com/events.cfm?CalendarID=2.
AMRI: 16.20 (+0.03)
AMRI Licenses CRISPR-Cas9 Gene Editing Technology
PR Newswire - Tue Aug 23, 3:05PM CDT
AMRI (NASDAQ: AMRI) today announced that it entered into a non-exclusive commercial license agreement with the Broad Institute of MIT and Harvard for the use of CRISPR-Cas9 gene editing technology and has completed several projects for its customers. The company will continue to use the technology to enhance its drug discovery service offerings and internal research and development. Financial terms were not disclosed.
AMRI: 16.20 (+0.03)
Update in Lawsuit for Investors in Albany Molecular Research, Inc. shares announced by Shareholders Foundation
GlobeNewswire - Tue Aug 23, 9:05AM CDT
The Shareholders Foundation, Inc. announces that a lawsuit is pending in New York on behalf of certain purchasers of shares of Albany Molecular Research, Inc. (NASDAQ:AMRI) over alleged Securities Laws Violations by Albany Molecular Research.
AMRI: 16.20 (+0.03)
Ryan & Maniskas, LLP Announces Investigation of Albany Molecular Research Inc.
PR Newswire - Wed Aug 10, 5:00PM CDT
Ryan & Maniskas, LLP is investigating potential claims against the board of directors of Albany Molecular Research, Inc. ("Albany Molecular" or the "Company"
(NASDAQ: AMRI). AMRI: 16.20 (+0.03)
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Albany Molecular Research, Inc. (AMRI)
PR Newswire - Tue Aug 09, 9:15AM CDT
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Albany Molecular Research, Inc. ("Amri" or the "Company"
(NASDAQ: AMRI). Such investors are advised to contact Peretz Bronstein or his investor relations analyst, Yael Hurwitz at info@bgandg.com or 212-697-6484. AMRI: 16.20 (+0.03)
Robbins Arroyo LLP Is Investigating the Officers and Directors of Albany Molecular Research, Inc. (AMRI) on Behalf of Shareholders
BusinessWire - Mon Aug 08, 12:03PM CDT
Shareholder rights law firm Robbins Arroyo LLP is investigating whether certain officers and directors of Albany Molecular Research, Inc. (NASDAQGS: AMRI) breached their fiduciary duties to the company and its shareholders by failing to implement adequate internal controls over the company's management and disclosure procedures. Albany Molecular Research, a contract research and manufacturing company, provides integrated drug discovery, development, and manufacturing services primarily in the United States, Europe, and Asia.
AMRI: 16.20 (+0.03)
AMRI Announces Second Quarter 2016 Results
PR Newswire - Thu Aug 04, 6:30AM CDT
AMRI (NASDAQ: AMRI) today reported financial and operating results for the second quarter ended June 30, 2016 and provided an update to its outlook for 2016.
AMRI: 16.20 (+0.03)
(0)
(0)Scroll down for more posts ▼